<DOC>
	<DOCNO>NCT01881581</DOCNO>
	<brief_summary>This randomize , double-blind placebo-controlled dose-escalation clinical trial evaluate safety immunogenicity DNA modify vaccinia virus Ankara ( MVA ) HIV-1 vaccine subject receive stable highly active antiretroviral therapy ( HAART ) HIV-1 RNA &lt; 50 copies/mm3 CD4+ T cell count ≥ 350 cells/mm3 .</brief_summary>
	<brief_title>Safety Immunogenicity Recombinant HIV Vaccines HIV/AIDS</brief_title>
	<detailed_description>HIV-infected patient treated antiretroviral therapy prolong period time may show decreased level HIV-specific immune response . In patient , prime-boost vaccine strategy may induce humoral cell-mediated immunity . The hypothesis study vaccine strategy select safe immunogenic patient population test . Patients continue antiretroviral medication throughout course study . Three group patient receive dose-escalation ( 0.5mg , 2mg 4mg ) intramuscular injection DNA vaccine ( D-GPEi ) respectively , three group patient receive dose-escalation ( 3×10^7pfu , 1×10^8pfu 3×10^8pfu ) intradermal injection MVA vaccine ( M-GPE ) , two week post immunization lower dose , vaccine safe well tolerant , next dose immunization begin . After maximum tolerate dose DNA MVA identify , DNA prime/ MVA boosting test another two group patient . Lower maximum tolerate dose D-GPEi use week 0 1 , low maximum tolerate dose M-GPE use week 2 3 , patient monitor safety 72 hour immunization . In addition , patient record adverse event diary . Patients regular physical exam , pregnancy test , blood drawn virologic immunologic assessment . The induction HIV-specific response measure .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Are willing participate study available followup duration study . Men woman age 1850 year . Are HIVpositive . Have take stable antiHIV drug least 6 month . CD4 count ≥ 350 cells/mm3 Plasma viral load &lt; 50 copies/ml . Willing use acceptable form contraception least 21 day prior first vaccination 56 day last vaccination . Pregnancy breastfeed . History previous vaccination HIV1 vaccine . Use immunoinhibitory agent , corticosteroid cytotoxic drug oral administration , injection route inhalation route within 6 month study entry ( But corticosteroid use allergic rhinitis skin topical application corticosteroid include ) ; Use immunomodulatory agent include limited interleukin2 ( IL2） granulocytemacrophage colonystimulating factor ( GMCSF ) within 30 day study entry . Use blood product within 3 month study entry . Use experimental drug within 3 month study entry . Any immunization within 3 month study entry . Comply follow items： Active pulmonary tuberculosis； History serious adverse reaction vaccines； Serious asthma； Have untreated thyroid disease ; Syphilis Laboratory values（Comply follow items） : Hemoglobin &lt; 100 g/L ( male subject ) ， &lt; 90 g/L ( female subject ) ； Absolute neutrophil count ≤ 1000 cells/mm3； Serum creatinine ≥15 mg/L，endogenous creatinine clearance rate &lt; 50 ml/min； alanine aminotransferase（ALT） , aspartate aminotransferase ( AST ) ≥3× upper limit normal range； Total bilirubin ≥2× upper limit normal range Clinically significant electrocardiogram change . Hypertension ( If well control medication less 150/100mmHg , exclude ) cardiac disease； Any medical , psychiatric , social condition , occupational reason judge investigator would limit evaluation subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Therapeutic</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HIV</keyword>
	<keyword>MVA</keyword>
	<keyword>DNA</keyword>
</DOC>